AC Bioscience
Pre-clinicalAC Bioscience is pioneering a new class of cancer therapeutics by targeting the unique metabolic dependencies of tumor cells. The company's discovery platform integrates computational biology, metabolomics, and functional genomics to identify critical nodes in cancer metabolism. Its most advanced programs inhibit key enzymes involved in amino acid and nucleotide synthesis pathways, aiming to induce synthetic lethality in genetically defined cancers. The company operates as a private, pre-clinical stage biotech based in Switzerland.
AI Company Overview
AC Bioscience is pioneering a new class of cancer therapeutics by targeting the unique metabolic dependencies of tumor cells. The company's discovery platform integrates computational biology, metabolomics, and functional genomics to identify critical nodes in cancer metabolism. Its most advanced programs inhibit key enzymes involved in amino acid and nucleotide synthesis pathways, aiming to induce synthetic lethality in genetically defined cancers. The company operates as a private, pre-clinical stage biotech based in Switzerland.
Technology Platform
A proprietary integrated platform combining computational biology, metabolomics, and functional genomics to identify and validate novel metabolic vulnerabilities in cancer cells for therapeutic targeting.
Funding History
4Total raised: $35M
Opportunities
Risk Factors
Competitive Landscape
Competes with leaders like Agios Pharmaceuticals and other biotechs in cancer metabolism. Differentiation likely stems from its proprietary target discovery platform, novel chemical matter against unique metabolic nodes, and a focused biomarker-driven development strategy for specific genetic subsets of cancer.
Company Info
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile